 Genprex Inc NASDAQ:GNPX, a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, announced that it has started clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer NSCLC. Acclaim-2 is an open-label, multi-center Phase 12 clinical trial that combines Genprexs lead drug candidate, REQORSA immunogene therapy, with Merck Cos Keytruda in patients with late-stage NSCLC who are low expressors 1 to 49 of the protein programmed death-ligand 1 PD-L1, said the company. 